BioCryst, Neopharmed Sign $345M Europe HAE Deal
RESEARCH TRIANGLE PARK, NORTH CAROLINA, May 04, 2026 BioCryst Pharmaceuticals has announced a strategic European licensing agreement with an...
plasma kallikrein inhibitor
Advertisement
KalVista Showcases EKTERLY Data at AAAAI 2026 Meet
FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world...
50,000 + Uses of the Syn-One Test® Mark Major Diagnostic Milestone
Scottsdale, AZ — November 6, 2025 : CND Life Sciences (CND) announced the completion of its 50,000th Syn-One Test®,...
KalVista Pharmaceuticals Highlights EKTERLY®’s Promise for Children and Strong Patient Satisfaction in HAE Treatment
Framingham, Massachusetts & Salisbury, England — November 6, 2025 : KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) presented new data at...
Advertisement
